The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead's drugs, which could have swapped out an ingredient for a safer alternative. OAKLAND, Calif. (CN) — The ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was ...

Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise. Shortly after the turn of the century, Gilead Sciences took a ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...